logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line

< Back

Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line

Drugs

Cancer and Palliative Care

September 2017


Nivolumab is a type of protein designed to attach to a certain type of white blood cells called the T cells. T cells are part of the immune system needed to attack the cancer. Nivolumab acts to improve the activity of T cells, thereby increasing the ability of the immune system to kill cancer cells. Ipilimumab is another type of protein that acts in a different way to increase the activity of T cells. If licenced, nivolumab in combination with ipilimumab will offer additional treatment option to prolong lives of this patient group.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Nivolumab (Opdivo) with Ipilimumab (Yervoy)



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts